This page is intended for healthcare professionals

This page is intended for healthcare professionals

Testosterone treatments are contraindicated in cases of known or suspected prostate cancer or breast carcinoma.1

Testosterone Therapy Monitoring

In addition to the general testosterone therapy monitoring described in the table above, the Testogel 16.2 mg/g gel Summary of Product Characteristics also recommends that the following be monitored regularly: haemoglobin, liver function tests, and lipid profile. Please refer to the SPC for further information.

REFERENCES:

1.The British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice. 2017. Available at: http://www.bssm.org.uk/wp-content/uploads/2018/09/guidelines-on-adult-testosterone-deficiency-with-statements-for-uk-practice.pdf Accessed November 2018.

ADVERSE EVENT REPORTING

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: drugsafety@besins-healthcare.com

This page is intended for healthcare professionals

© 2018 BESINS HEALTHCARE LTD.TES/2018/075F Date of Preparation November 2018.

API